{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:50:22Z","timestamp":1791931822196,"version":"4.3.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,3,7]],"date-time":"2014-03-07T00:00:00Z","timestamp":1394150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2014,3,7]],"date-time":"2014-03-07T00:00:00Z","timestamp":1394150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1007\/s10637-014-0071-z","type":"journal-article","created":{"date-parts":[[2014,3,6]],"date-time":"2014-03-06T03:21:30Z","timestamp":1394076090000},"page":"653-660","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":94,"title":["A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors"],"prefix":"10.1007","volume":"32","author":[{"given":"Colin D.","family":"Weekes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muralidhar","family":"Beeram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony W.","family":"Tolcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyriakos P.","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia","family":"Gore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priti","family":"Hegde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Mason","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer K.","family":"Brachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amita","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,3,7]]},"reference":[{"key":"71_CR1","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1146\/annurev-neuro-060909-152829","volume":"33","author":"SJ Tam","year":"2010","unstructured":"Tam SJ, Watts RJ (2010) Connecting vascular and nervous system development: angiogenesis and the blood-brain barrier. Annu Rev Neurosci 33:379\u2013408","journal-title":"Annu Rev Neurosci"},{"key":"71_CR2","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S0092-8674(00)80534-6","volume":"90","author":"Z He","year":"1997","unstructured":"He Z, Tessier-Lavigne M (1997) Neuropilin is a receptor for the axonal chemorepellent semaphorin III. Cell 90:739\u201351","journal-title":"Cell"},{"key":"71_CR3","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0092-8674(00)81402-6","volume":"92","author":"S Soker","year":"1998","unstructured":"Soker S, Takashima S, Quan H et al (1998) Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92:735\u201345","journal-title":"Cell"},{"key":"71_CR4","doi-asserted-by":"crossref","first-page":"4895","DOI":"10.1242\/dev.126.21.4895","volume":"126","author":"T Kawasaki","year":"1999","unstructured":"Kawasaki T, Kitsukawa T, Bekku Y (1999) A requirement for neuropilin-1 in embryonic vessel formation. Development 126:4895\u2013902","journal-title":"Development"},{"key":"71_CR5","doi-asserted-by":"publisher","first-page":"24818","DOI":"10.1074\/jbc.M200730200","volume":"277","author":"R Mamluk","year":"2002","unstructured":"Mamluk R, Gechtman Z, Kutcher ME, Gasiunas N, Gallagher J, Klagsbrun M (2002) Neuropilin-1 binds vascular endothelial growth factor 165, placenta growth factor-2, and heparin via its b1b2 domain. J Biol Chem 277:24818\u201325","journal-title":"J Biol Chem"},{"key":"71_CR6","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1073\/pnas.022017899","volume":"99","author":"S Takashima","year":"2002","unstructured":"Takashima S, Kitakaze M, Asakura M et al (2002) Targeting of both mouse neuropilin-1 and neuropilin-2 genes severely impairs developmental yolk sac and embryonic angiogenesis. Proc Natl Acad Sci U S A 99:3657\u201362","journal-title":"Proc Natl Acad Sci U S A"},{"key":"71_CR7","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/dvdy.20148","volume":"231","author":"H Gerhardt","year":"2004","unstructured":"Gerhardt H, Ruhrberg C, Abramsson A, Fujisawa H, Shima D, Betsholtz C (2004) Neuropilin-1is required for endothelial tip cell guidance in the developing central nervous system. Dev Dyn 231:503\u20139","journal-title":"Dev Dyn"},{"key":"71_CR8","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.3390\/cancers3021899","volume":"3","author":"C Grandclement","year":"2011","unstructured":"Grandclement C, Borg C (2011) Neuropilins: a new target for cancer therapy. Cancers 3:1899\u20131928","journal-title":"Cancers"},{"key":"71_CR9","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.yexcr.2005.11.024","volume":"312","author":"DR Bielenberg","year":"2006","unstructured":"Bielenberg DR, Pettaway CA, Takashima S et al (2006) Neuropilins in neoplasms: expression, regulation, and function. Exp Cell Res 312:584\u201393","journal-title":"Exp Cell Res"},{"key":"71_CR10","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nature10525","volume":"478","author":"B Beck","year":"2011","unstructured":"Beck B, Driessens G, Goossens S et al (2011) A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumors. Nature 478:399\u2013403","journal-title":"Nature"},{"key":"71_CR11","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1007\/s11095-012-0781-x","volume":"29","author":"Y Xin","year":"2012","unstructured":"Xin Y, Bai S, Damico-Beyer LA et al (2012) Anti-neuropilin-1 (MRNP1685A): unexpected pharmacokinetic differences across species, from preclinical models to humans. Pharm Res 29:2512\u201321","journal-title":"Pharm Res"},{"key":"71_CR12","doi-asserted-by":"crossref","unstructured":"Xin Y, Li J, Wu J, et al. (2012b) Pharmacokinetic and pharmacodynamic analysis of circulating biomarkers of anti-NRP1, a novel anti-angiogenesis agent, in two Phase I trials in patients with advanced solid tumors, Clinical Cancer Research, in press.","DOI":"10.1158\/1078-0432.CCR-12-1652"},{"key":"71_CR13","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.jmb.2006.11.021","volume":"366","author":"W-C Liang","year":"2007","unstructured":"Liang W-C, Dennis MS, Stawicki S et al (2007) Function blocking antibodies to neuropilin-1 generated from a designed human synthetic antibody phage library. J Mol Biol 366:815\u201329","journal-title":"J Mol Biol"},{"key":"71_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ccr.2006.10.018","volume":"11","author":"Q Pan","year":"2007","unstructured":"Pan Q, Chanthery Y, Liang W-C (2007) Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 11:53\u201367","journal-title":"Cancer Cell"},{"key":"71_CR15","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1586\/eci.09.31","volume":"5","author":"PJ Bugelski","year":"2009","unstructured":"Bugelski PJ, Achuthanandam R, Capocasale RJ et al (2009) Monoclonal antibody-induced cytokine-release syndrome. Expert Rev Clin Immunol 5:499\u2013521","journal-title":"Expert Rev Clin Immunol"},{"key":"71_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1365-3083.2005.01640.x","volume":"62","author":"CQ Xia","year":"2005","unstructured":"Xia CQ, Peng R, Beato F, Clare-Salzler MJ (2005) Dexamethasone induces IL-10-producing monocyte-derived dendritic cells with durable immaturity. Scand J Immunol 62:45\u201354","journal-title":"Scand J Immunol"},{"key":"71_CR17","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.clim.2011.11.011","volume":"142","author":"MA Boks","year":"2012","unstructured":"Boks MA, Kager-Groenland JR, Haasjes MS, Zwaginga JJ, van Ham SM, ten Brinke A (2012) IL-10-generated tolerogenic dendritic cells are optimal for functional regulatory T cell induction\u2013a comparative study of human clinical-applicable DC. Clin Immunol 142:332\u201342","journal-title":"Clin Immunol"},{"key":"71_CR18","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/nrrheum.2010.4","volume":"6","author":"C Gabay","year":"2010","unstructured":"Gabay C, Lamacchia C, Palmer G (2010) IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol 6:232\u201341","journal-title":"Nat Rev Rheumatol"},{"key":"71_CR19","doi-asserted-by":"crossref","unstructured":"Darbonne WC, Du X, Dhawan P, et al (2011) Mechanism for platelet reduction in anti-neuropilin-1 (MNRP1685A)-treated phase I patients. J Clin Oncol 29","DOI":"10.1200\/jco.2011.29.15_suppl.e13598"},{"key":"71_CR20","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nrclinonc.2009.110","volume":"6","author":"A Grothey","year":"2009","unstructured":"Grothey A, Galanis E (2009) Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 6:507\u201318","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"71_CR21","first-page":"x118","volume":"23","author":"FA Raja","year":"2010","unstructured":"Raja FA, Chopra N, Ledermann JA (2010) Optimal first-line treatment in ovarian cancer. Ann Oncol 23(10):x118\u2013x127","journal-title":"Ann Oncol"},{"key":"71_CR22","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1042\/BJ20071639","volume":"411","author":"C Pellet-Many","year":"2008","unstructured":"Pellet-Many C, Frankel P, Jia H (2008) Neuropilins: structure, function and role in disease. Biochem J 411:211\u201326","journal-title":"Biochem J"},{"key":"71_CR23","doi-asserted-by":"crossref","unstructured":"Pataik A, LoRusso PM, Messersmith W (2013) A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. (in press)","DOI":"10.1007\/s00280-014-2426-8"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-014-0071-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-014-0071-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-014-0071-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-014-0071-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T23:50:07Z","timestamp":1678492207000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-014-0071-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,7]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["71"],"URL":"https:\/\/doi.org\/10.1007\/s10637-014-0071-z","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,7]]},"assertion":[{"value":"15 October 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}